Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Ex-Pfizer SVP takes the helm at BioClinica
BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer ($PFE), where he worked as senior vice president and worldwide head of development operations. The move sees Hubbard step back into the vendor and service provider sector, a field with which he is familiar. Prior to joining Pfizer, Hubbard headed up clinical research services at Icon ($ICLR). Release
Vaccines > Julie Gerberding, president of Merck's ($MRK) vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday. Release Biotech > Innocoll ($INNL) appointed Tony Zook as the company's CEO. Release > John Tchelingerian joined Promethera Biosciences as the new chairman of the board. Release > Batu Biologics brought on Gerry Berg as its chief financial officer. Release > XTL Biopharmaceuticals ($XTLB) appointed Jonathan Schapiro and Dobroslav Melamed to its board of directors. Release > Amarantus BioSciences appointed Amgen ($AMGN) co-founder Joseph Rubinfeld to its board of directors. Release > Leidos hired Steven Russell as its senior vice president for sales and strategic accounts. Release > ATS Labs, now Accuratus Lab Services, brought on Eric Hess as its CEO. Release > Dr. Yan Sun joined Beyondspring Pharmaceuticals as the principal investigator for its Phase III lung cancer trial of plinabulin. Release > Arcturus Therapeutics appointed Dr. Michael Hodges to its scientific advisory board. Release > INC Research ($INCR) appointed Richard Kender to its board of directors. Release > Cytovance Biologics appoints Don Wuchterl as chief operating officer. Release > Soligenix appointed Oreola Donini as senior vice president and chief scientific officer. Release > CBSET appointed Dr. Haim Danenberg as chief scientific adviser. Release > OvaScience ($OVAS) promoted Arthur Tzianabos to president, Theresa McNeely to EVP, and appointed David Harding as chief commercial officer. Release > Dan Glickman joined Pathway Genomics' Strategic Advisory Board. Release > The Illinois Biotechnology Industry Organization elected Daniel Brennan, Jamie Oldani, Susanne Resatz and Geeta Vemuri to its board of directors. Release > Elise Brownell was appointed as Amarantus Biosciences' SVP of operations and project management. Release > Dr. Fred T. Fiedorek was named chief medical officer by Rhythm. Release Pharma > Aquinox Pharmaceuticals appointed David Mitchell as its vice president of global regulatory affairs and quality assurance. Release > Don deBethizy joins Berlin-based Noxxon Pharma's supervisory board. Release > Thomas G. Auchincloss Jr. will join Concert Pharmaceuticals' ($CNCE) board of directors and will serve as the independent chair of the board's audit committee. Release > Agios Pharmaceuticals ($AGIO) appoints Kaye Foster-Cheek to its board of directors. Release > Christine Silverstein joins Relmada Therapeutics as director of investor relations. Release > Parnell Pharmaceuticals Holdings shakes up its management team, appointing Edward Robb as chief scientific officer, Andy Ferrigno as vice president of global sales and Thomas Duley as a member of the board of directors and member of the audit committee. Release CRO > Peter Kant joined SRI International as the executive director of its Center for Science, Technology and Economic Development. Release Biotech Research > The Glenn Foundation for Medical Research brought on Kevin Lee as its senior adviser. Release Medical Devices > HeartFlow appointed former Johnson & Johnson ($JNJ) CEO William Weldon to its board of directors. Release |
||||||||||
